Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $40.45 USD
Change Today +0.84 / 2.12%
Volume 2.8M
A On Other Exchanges
New York
As of 8:04 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

agilent technologies inc (A) Key Developments

Agilent Technologies Enters into Collaboration with Bioprocessing Technology Institute

Agilent Technologies has entered into collaboration with Bioprocessing Technology Institute on new bioanalytical methods for analyzing specific protein-linked sugar compounds. The collaboration will centre on developing Agilent's proprietary AssayMAP Bravo platform, which in combination with a mass spectrometer can be used in the production of therapeutic glycoproteins to develop analysis methods for N- and O-linked glycans. The partnership is aimed at meeting demand for analytical tests for treatments based on glycoproteins, by leveraging Agilent's technology platform and BTI's bioprocessing expertise to create more rapid standardized glycan analysis. The collaboration builds on Agilent Technologies and ASTAR's previous memorandum of understanding to collaborate on research into biologics and vaccines, and underlines Singapore's importance as an R&D centre.

Agilent Technologies Launches New Products for Analyzing Biotherapeutics

Agilent Technologies Inc. announced two additions to its AdvanceBio product family, designed to provide rapid, reproducible results for scientists in the biopharmaceutical industry. Agilent introduced the products—the AdvanceBio glycan-mapping workflow and the AdvanceBio oligonucleotide column—at HPLC 2015, an international symposium being held in Geneva, Switzerland, this week. The company’s new AdvanceBio glycan-mapping workflow is a complete consumables workflow for deglycosylation, 2-AB labeling and HILIC glycan analysis using mass spectrometry and fluorescence detection. This unique workflow features AdvanceBio glycan-mapping columns, glycan standards and N-glycan sample-preparation kits, along with all the consumable components researchers require. The product’s comprehensive guides and standard methods provide researchers with everything they need to quickly identify and quantify glycans in a way that is easily reproducible.

Agilent Technologies Inc. Introduces Second Automatic Sampler for 1290 Infinity II LC System

Agilent Technologies Inc. introduced a second automatic sampler for its ultra-high-performance 1290 Infinity II LC system. The new 1290 Infinity II Vialsampler shortens injection cycles, lowers carryover and enlarges sample capacity at a pressure range of up to 1300 bar. The new module is being shown for the first time at HPLC 2015, an international symposium on high-performance liquid phase separations and related techniques, in Geneva, Switzerland. Highly integrated, the new module combines autosampler features with options to integrate both a column oven and a sample cooler. It offers analytical laboratories a cost-effective way to experience the advantages of ultra-high-pressure liquid chromatography.

Agilent Technologies Announces Updates to SurePrint Gene Expression Microarrays

Agilent Technologies Inc. has announced updates to its SurePrint gene expression microarrays for messenger RNA profiling applications for human, mouse and rat models. The updates improve coding and noncoding content, which will provide up-to-date tools for researchers to investigate expression patterns on a highly accessible platform. Agilent developed the updates to its SurePrint G3 Human v3 gene expression microarray in collaboration with Ghent University for complete coverage of the LNCipedia 2.1 database to assay high-confidence, long noncoding RNA (lncRNA) transcripts. LncRNAs (noncoding RNA longer than 200 nucleotides) modify gene regulation through direct interactions with DNA, RNA and proteins to enable target-specific or system-wide modulation. The broad but critical role of lncRNAs can be seen in their association with cancer, cardiovascular and neurodegenerative diseases. Agilent's redesigned gene expression microarrays are high-quality signature capture tools for efficient analysis of genes or pathways of interest with broad applications that range from aiding in disease stratification to elucidating drug mechanisms. Measuring both types of RNA in a single assay provides insight into the biological association between mRNA and lncRNA from relative expression levels. The key is having a good balance of coding and long noncoding features, and LNCipedia 2.1 is an optimal source to pair with Agilent's gene expression content.

Agilent Technologies Launches SureSelect Human All Exon V6, V6+UTR and V6+COSMIC

Agilent Technologies Inc. has expanded its SureSelect target-enrichment product family by launching the SureSelect Human All Exon V6, V6+UTR and V6+COSMIC. The new products are designed to address the current limitations of exome sequencing, giving researchers better coverage of hard-to-capture regions and providing deep coverage of relevant regions, with minimal sequencing. By providing the most comprehensive, up-to-date exome design, these new products will enable researchers to delve deeper into both constitutional diseases and cancers. The Human All Exon V6 is an important addition to strong NGS portfolio for constitutional disease research. It targets hard-to-capture and multi-mapping regions that had proven challenging for current exome products on the market. Along with SureSelectQXT, Agilent now provides the fast hybridization-based enrichment solution, which will add great value in any research setting, enabling the identification of more variants with greatly reduced turnaround time and at lower sequencing cost. The new products cover more regions (including previously recognized gaps), increase the sensitivity of variant calling, and minimize false negative calls. SureSelect Human All Exon V6+UTR adds untranslated regions of the exome for translational research, while V6+COSMIC adds data from the cancer research database known as the Catalogue Of Somatic Mutations In Cancer. This latest design, optimized to cover targeted regions in greater detail, can also be blended with any custom capture design, enabling an exome tailored for specific applications. The new SureSelect products are the latest in a line of genomics solutions Agilent has announced so far this year, including: OneSeq, the all-in-one target enrichment product for identifying genome-wide copy number variations and mutations; and the SureSelect clinical research exome, SureSelect focused exome and ClearSeq inherited disease research panel. These expert-optimized designs enable targeted analysis of disease-associated regions on either high-output or desktop sequencers. The new products are compatible with the custom design capabilities of SureDesign, the sample quality control provided by the Agilent 2100 Bioanalyzer and 2200 Tapestation, the reproducible performance of the Bravo Automated Liquid Handling Platform, and the guided analysis workflows enabled by SureCall software.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
A:US $40.45 USD +0.84

A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AMETEK Inc $52.45 USD +0.44
Furukawa Electric Co Ltd ¥199.00 JPY -4.00
NVIDIA Corp $19.73 USD +0.42
NXP Semiconductors NV $91.04 USD +2.82
STMicroelectronics NV €7.02 EUR +0.065
View Industry Companies

Industry Analysis


Industry Average

Valuation A Industry Range
Price/Earnings 25.1x
Price/Sales 1.9x
Price/Book 3.2x
Price/Cash Flow 40.6x
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGILENT TECHNOLOGIES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at